|
1
|
Siegel R, DeSantis C, Virgo K, Stein K,
Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al:
Cancer treatment and survivorship statistics, 2012. CA Cancer J
Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bhoo-Pathy N, Yip CH, Hartman M, Uiterwaal
CS, Devi BC, Peeters PH, Taib NA, van Gils CH and Verkooijen HM:
Breast cancer research in Asia: Adopt or adapt Western knowledge?
Eur J Cancer. 49:703–709. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bedard PL, Di Leo A and Piccart-Gebhart
MJ: Taxanes: Optimizing adjuvant chemotherapy for early-stage
breast cancer. Nat Rev Clin Oncol. 7:22–36. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Murray S, Briasoulis E, Linardou H,
Bafaloukos D and Papadimitriou C: Taxane resistance in breast
cancer: Mechanisms, predictive biomarkers and circumvention
strategies. Cancer Treat Rev. 38:890–903. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maestro R, Dei Tos AP, Hamamori Y,
Krasnokutsky S, Sartorelli V, Kedes L, Doglioni C, Beach DH and
Hannon GJ: Twist is a potential oncogene that inhibits apoptosis.
Genes Dev. 13:2207–2217. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Valsesia-Wittmann S, Magdeleine M,
Dupasquier S, Garin E, Jallas AC, Combaret V, Krause A, Leissner P
and Puisieux A: Oncogenic cooperation between H-Twist and N-Myc
overrides failsafe programs in cancer cells. Cancer Cell.
6:625–630. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang X, Ling MT, Guan XY, Tsao SW, Cheung
HW, Lee DT and Wong YC: Identification of a novel function of
TWIST, a bHLH protein, in the development of acquired taxol
resistance in human cancer cells. Oncogene. 23:474–482. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang J, Mani SA, Donaher JL, Ramaswamy S,
Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and
Weinberg RA: Twist, a master regulator of morphogenesis, plays an
essential role in tumor metastasis. Cell. 117:927–939. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C,
Zhang X, Chua CW, Chan KW, Chan FL, Glackin C, et al: Up-regulation
of TWIST in prostate cancer and its implication as a therapeutic
target. Cancer Res. 65:5153–5162. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kunjachan S, Rychlik B, Storm G, Kiessling
F and Lammers T: Multidrug resistance: Physiological principles and
nanomedical solutions. Adv Drug Deliv Rev. 65:1852–1865. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lu D, Shi HC, Wang ZX, Gu XW and Zeng YJ:
Multidrug resistance-associated biomarkers PGP GST-pi, Topo-II and
LRP as prognostic factors in primary ovarian carcinoma. Br J Biomed
Sci. 68:69–74. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Longley DB and Johnston PG: Molecular
mechanisms of drug resistance. J Pathol. 205:275–292. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Scheffer GL, Schroeijers AB, Izquierdo MA,
Wiemer EA and Scheper RJ: Lung resistance-related protein/major
vault protein and vaults in multidrug-resistant cancer. Curr Opin
Oncol. 12:550–556. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Scheffer GL, Wijngaard PL, Flens MJ,
Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC and
Scheper RJ: The drug resistance-related protein LRP is the human
major vault protein. Nat Med. 1:578–582. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang JC: Cellular roles of DNA
topoisomerases: A molecular perspective. Nat Rev Mol Cell Biol.
3:430–440. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Coss A, Tosetto M, Fox EJ, Sapetto-Rebow
B, Gorman S, Kennedy BN, Lloyd AT, Hyland JM, O'Donoghue DP,
Sheahan K, et al: Increased topoisomerase IIalpha expression in
colorectal cancer is associated with advanced disease and
chemotherapeutic resistance via inhibition of apoptosis. Cancer
Lett. 276:228–238. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Borst P, Evers R, Kool M and Wijnholds J:
A family of drug transporters: The multidrug resistance-associated
proteins. J Natl Cancer Inst. 92:1295–1302. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang L, Mao N, Tan RZ, Wang HL, Wen J, Liu
YH, Furhad M and Fan JM: Ginsenoside Rg1 reduces
aldosterone-induced autophagy via the AMPK/mTOR pathway in NRK-52E
cells. Int J Mol Med. 36:518–526. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Drummond DC, Noble CO, Kirpotin DB, Guo Z,
Scott GK and Benz CC: Clinical development of histone deacetylase
inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol.
45:495–528. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Atalay C, Deliloglu Gurhan I, Irkkan C and
Gunduz U: Multidrug resistance in locally advanced breast cancer.
Tumour Biol. 27:309–318. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kovalev AA, Tsvetaeva DA and Grudinskaja
TV: Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the
development of primary and acquired multiple drug resistance in
patients with early and metastatic breast cancer. Exp Oncol.
35:287–290. 2013.PubMed/NCBI
|
|
25
|
Yoneyama H, Takizawa-Hashimoto A, Takeuchi
O, Watanabe Y, Atsuda K, Asanuma F, Yamada Y and Suzuki Y: Acquired
resistance to gemcitabine and cross-resistance in human pancreatic
cancer clones. Anticancer Drugs. 26:90–100. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Scagliotti GV, Novello S and Selvaggi G:
Multidrug resistance in non-small-cell lung cancer. Ann Oncol. 10
Suppl 5:S83–S86. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mechetner E, Kyshtoobayeva A, Zonis S, Kim
H, Stroup R, Garcia R, Parker RJ and Fruehauf JP: Levels of
multidrug resistance (MDR1) P-glycoprotein expression by human
breast cancer correlate with in vitro resistance to taxol and
doxorubicin. Clin Cancer Res. 4:389–398. 1998.PubMed/NCBI
|
|
28
|
Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD
and Wang LH: Twist transcriptionally up-regulates AKT2 in breast
cancer cells leading to increased migration, invasion, and
resistance to paclitaxel. Cancer Res. 67:1979–1987. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang X, Wang Q, Ling MT, Wong YC, Leung
SC and Wang X: Anti-apoptotic role of TWIST and its association
with Akt pathway in mediating taxol resistance in nasopharyngeal
carcinoma cells. Int J Cancer. 120:1891–1898. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pham CG, Bubici C, Zazzeroni F, Knabb JR,
Papa S, Kuntzen C and Franzoso G: Upregulation of Twist-1 by
NF-kappaB blocks cytotoxicity induced by chemotherapeutic drugs.
Mol Cell Biol. 27:3920–3935. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q,
Tang F, Chen ZQ, Liu XP and Xu ZD: Twist1-mediated
adriamycin-induced epithelial-mesenchymal transition relates to
multidrug resistance and invasive potential in breast cancer cells.
Clin Cancer Res. 15:2657–2665. 2009. View Article : Google Scholar : PubMed/NCBI
|
